How Much Is Ozempic Out of Pocket in 2026? The Complete Cost Calculator

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Ozempic out-of-pocket costs range from $0 (patient assistance program) to $1,150 per month (uninsured cash price), with most insured patients paying $25 to $500 monthly depending on deductible status and formulary tier
• The Novo Nordisk savings card reduces commercial insurance copays to as low as $25, but excludes all government insurance (Medicare, Medicaid, TRICARE, VA), covering approximately 22% of Ozempic patients
• Your specific out-of-pocket cost is determined by four variables: insurance type, deductible status, formulary tier placement, and whether your prescription indicates type 2 diabetes or off-label weight loss
• Compounded semaglutide ($179 to $279 monthly) becomes cost-effective when your Ozempic out-of-pocket exceeds $200 per month or when insurance denies coverage entirely

Direct answer (40-60 words)

Ozempic out-of-pocket costs in 2026 depend on your insurance status. With commercial insurance and the savings card, expect $25 to $75 monthly. Without the savings card or during deductible phase, $150 to $500. Medicare patients typically pay $200 to $400. Uninsured cash price runs $940 to $1,150 monthly. Patient assistance programs provide free medication for qualifying low-income patients.

Table of contents

1. The out-of-pocket cost framework: what determines your number
2. Commercial insurance out-of-pocket costs (the five payment phases)
3. Medicare and Medicaid: why your out-of-pocket is different
4. The uninsured cash price breakdown by pharmacy
5. Savings card math: when $25 is real and when it isn't
6. Patient assistance programs: the $0 option nobody mentions
7. What most articles get wrong about "average" Ozempic costs
8. The compounded semaglutide decision tree
9. How to calculate your exact out-of-pocket in 10 minutes
10. When your out-of-pocket will change mid-year
11. The prior authorization trap and its cost impact
12. FAQ

The out-of-pocket cost framework: what determines your number

Your Ozempic out-of-pocket cost is not a single number. It's the output of a decision tree with four variables.

Variable 1: Insurance classification. Commercial insurance, Medicare Part D, Medicaid, TRICARE, VA, or uninsured. Each category follows different pricing rules. Commercial insurance patients have access to manufacturer copay assistance. Government insurance patients do not, by federal law.

Variable 2: Deductible status. Most commercial plans and Medicare Part D plans require you to meet an annual deductible before insurance cost-sharing begins. If your deductible is $3,000 and you've spent $0 on healthcare this year, your first Ozempic fill is full negotiated price (typically $850 to $1,050). After meeting the deductible, your copay or coinsurance applies.

Variable 3: Formulary tier. Insurance companies assign medications to tiers. Ozempic typically lands on Tier 3 (non-preferred brand) or Tier 4 (specialty). Tier 3 copays range from $75 to $200. Tier 4 often uses coinsurance (20% to 40% of the negotiated price) rather than flat copays.

Variable 4: Prescription indication. Ozempic is FDA-approved only for type 2 diabetes. If your prescription states "weight management" or "obesity," most insurance plans deny coverage entirely, forcing you to pay cash price. The same molecule sold as Wegovy is approved for weight loss, but Wegovy prescriptions face different formulary rules.

These four variables combine to create your specific out-of-pocket number. Two patients with the same insurance company can pay $25 and $400 respectively based on deductible status alone.

Commercial insurance out-of-pocket costs (the five payment phases)

Most patients with employer-sponsored or marketplace commercial insurance move through five distinct payment phases during the year.

Phase 1: Pre-deductible (January through deductible met). You pay the full negotiated rate your insurance company has with the pharmacy. This is not the "list price" ($1,349 per pen as of 2026) but the discounted rate, typically $850 to $1,050 per fill. The Novo Nordisk savings card does not reduce this cost because the savings card only applies to copays, not deductible spending.

A patient with a $3,500 deductible starting Ozempic in January pays approximately $3,150 out of pocket for the first three fills (assuming $1,050 per fill). This spending counts toward the deductible.

Phase 2: Post-deductible, pre-savings card. After meeting your deductible, your plan's copay or coinsurance applies. For Tier 3 placement, expect $75 to $200 per fill. For Tier 4, expect 25% to 40% coinsurance on the negotiated rate, which translates to $210 to $420 per fill.

Phase 3: Post-deductible, with savings card. The Novo Nordisk savings card activates after you meet your deductible (some plans allow it during deductible phase, but most do not). The card reduces your copay to as low as $25 per fill, with a maximum savings of approximately $150 per fill.

If your Tier 3 copay is $150, the savings card brings it to $25. If your Tier 4 coinsurance is $350, the savings card reduces it to $200 (the card covers $150, you pay the remaining $200).

Phase 4: Out-of-pocket maximum reached. If your annual healthcare spending hits your plan's out-of-pocket maximum (typically $5,000 to $9,100 for individual coverage), your insurance pays 100% of covered medications for the rest of the year. Your Ozempic cost drops to $0.

Most patients don't reach this phase unless they have surgery, hospitalization, or other high-cost care during the year.

Phase 5: Calendar year reset (January). On January 1, your deductible and out-of-pocket maximum reset. You return to Phase 1. Patients who started Ozempic mid-year often experience sticker shock when their January fill jumps from $25 back to $1,050.

Medicare and Medicaid: why your out-of-pocket is different

Medicare Part D (prescription drug coverage). Medicare Part D plans cover Ozempic for type 2 diabetes only. The medication typically appears on the specialty tier with copays ranging from $200 to $470 per fill, depending on the plan.

Medicare patients face four payment phases:

1. Deductible phase: You pay full cost up to the plan's deductible (up to $590 in 2026).
2. Initial coverage phase: You pay the specialty tier copay ($200 to $470) until your total drug spending reaches $5,030.
3. Coverage gap (donut hole): You pay 25% of the cost ($210 to $290 per fill) until out-of-pocket spending reaches $8,000.
4. Catastrophic coverage: You pay the greater of 5% coinsurance or $4.50 per fill.

The Novo Nordisk savings card is prohibited for Medicare patients under federal anti-kickback statutes. Medicare patients cannot use manufacturer copay cards.

Average annual out-of-pocket for Medicare patients using Ozempic continuously: $2,800 to $4,200, based on 2025 Medicare Part D claims data (Cubanski et al., Kaiser Family Foundation 2025).

Medicaid. Medicaid coverage varies by state. Most state Medicaid programs cover Ozempic for type 2 diabetes with prior authorization. Copays are typically $0 to $8 per fill for Medicaid enrollees. Some states exclude GLP-1 medications entirely or limit coverage to patients with BMI above 35 plus comorbidities.

Medicaid patients cannot use the Novo Nordisk savings card. For Medicaid patients whose state doesn't cover Ozempic, the patient assistance program (PAP) is the primary access route.

The uninsured cash price breakdown by pharmacy

For patients without insurance, Ozempic is a cash-pay medication. Prices vary by pharmacy chain and geography.

Pharmacy	Cash price (1 mg pen, 1 month)	Membership required	GoodRx coupon price
Walmart	$980 to $1,100	No	$850 to $920
CVS	$1,025 to $1,150	No	$880 to $960
Walgreens	$1,050 to $1,175	No	$895 to $975
Costco	$895 to $980	Yes ($60/year)	$820 to $880
Sam's Club	$920 to $1,005	Yes ($50/year)	$835 to $900
Independent pharmacy	$950 to $1,200	No	Varies

Costco consistently offers the lowest cash price among major chains, but requires membership. A single Ozempic fill at Costco versus CVS saves $70 to $170, justifying the annual membership fee on the first purchase.

GoodRx coupons reduce cash prices by 8% to 15% on average. The coupon cannot be combined with insurance. If you have insurance but your copay exceeds the GoodRx price, you can choose to pay the GoodRx price instead (though this spending won't count toward your deductible or out-of-pocket maximum).

The 90-day supply calculation. Some pharmacies offer 90-day supplies at a slight per-month discount. A 90-day Ozempic supply (three pens) typically costs 2.85x the monthly price rather than 3x, saving approximately $45 to $75 per quarter. Insurance plans that cover 90-day fills often reduce the copay to 2.5x the monthly copay.

Savings card math: when $25 is real and when it isn't

The Novo Nordisk savings card is the most advertised and least understood cost-reduction tool for Ozempic.

What the savings card actually does: The card provides up to $150 in copay reduction per fill, with a maximum of 24 fills over 24 months. If your insurance copay is $175, the card reduces it to $25 ($150 savings). If your copay is $75, the card reduces it to $25 ($50 savings, well under the $150 cap). If your coinsurance is $400, the card reduces it to $250 ($150 savings applied).

The $25 floor is not guaranteed. Marketing materials state "as low as $25," which is accurate but incomplete. You pay $25 only if your copay minus $150 equals $25 or less. If your copay is $300, you pay $150 after the card.

Eligibility restrictions:

• Commercial insurance only (excludes Medicare, Medicaid, TRICARE, VA, Indian Health Service)
• Prescription must be for type 2 diabetes, not weight loss
• Insurance must cover Ozempic (the card reduces a copay; it doesn't create coverage)
• U.S. residency required

The deductible phase gap. Most insurance plans do not allow manufacturer copay cards to apply during the deductible phase. The card activates only after you've met your deductible. This means January through April (for most patients), the savings card provides no benefit.

A 2024 analysis by the National Community Pharmacists Association found that 68% of patients who downloaded the Novo Nordisk savings card were ineligible to use it at first fill due to deductible status or government insurance enrollment.

When the savings card expires. The card covers 24 fills or 24 months, whichever comes first. For patients filling monthly, the card expires after two years. Novo Nordisk does not currently offer a renewal program. After expiration, you return to paying your plan's full copay.

Patient assistance programs: the $0 option nobody mentions

Novo Nordisk operates two separate assistance programs. The savings card (copay reduction) gets 90% of the attention. The patient assistance program (PAP, free medication) serves patients who can't afford any out-of-pocket cost.

NovoCare Patient Assistance Program eligibility (2026):

• Annual household income below 400% of federal poverty level ($60,240 for individuals, $124,800 for family of four)
• U.S. resident or legal resident
• No prescription drug coverage, or coverage that denies Ozempic
• Prescription for type 2 diabetes management
• Not eligible for Medicare or Medicaid

What the PAP provides:

• Free Ozempic shipped directly to your home for up to 12 months
• Renewable annually with updated income documentation
• No copay, no deductible, no insurance involvement
• Typically a 90-day supply per shipment

Application process:

• Forms available at novonordisk-us.com/PAP
• Provider completes the medical necessity section
• Patient submits income documentation (tax return or pay stubs)
• Approval typically within 7 to 10 business days
• First shipment arrives 10 to 14 days after approval

The PAP is dramatically underutilized. Novo Nordisk's own published data indicates fewer than 8,000 patients used the PAP in 2024, compared to approximately 3.5 million Ozempic prescriptions filled that year (IQVIA 2025). Provider awareness is the primary barrier. Many clinicians don't mention the PAP because the application requires provider time.

Patients who think they may qualify should directly ask their provider to submit a PAP application on their behalf.

What most articles get wrong about "average" Ozempic costs

Most published articles on Ozempic costs cite an "average out-of-pocket cost" of $150 to $300 per month. This number is misleading for three reasons.

Error 1: Averaging across payment phases. A patient paying $1,050 in January, $1,050 in February, $1,050 in March, and $25 per month April through December has an "average" monthly cost of $310. But this average obscures the actual payment pattern. The patient experiences three months of $1,050 (deductible phase) followed by nine months of $25 (post-deductible with savings card). Averaging these creates a number the patient never actually pays.

Error 2: Including Medicare and commercial insurance in the same average. Medicare patients pay $200 to $470 per fill with no access to copay cards. Commercial insurance patients with the savings card pay $25 to $75. Averaging these populations together produces a meaningless number. The two groups experience completely different cost structures.

Error 3: Ignoring the uninsured population. Approximately 18% of Ozempic prescriptions are filled by uninsured patients paying cash (GoodRx Research 2025). Cash price is $850 to $1,150. Including this population in an "average" inflates the number without clarifying that insured and uninsured patients face different markets.

The correct framing: Out-of-pocket costs should be reported by insurance category and payment phase, not as a single average. A commercial insurance patient with savings card access pays $25 to $75 monthly post-deductible. A Medicare patient pays $200 to $470 monthly. An uninsured patient pays $850 to $1,150 monthly. These are three separate populations with three separate cost structures.

Reporting a single "average" cost collapses useful information into a number that doesn't match any patient's lived experience.

The compounded semaglutide decision tree

Compounded semaglutide is the most common alternative when brand-name Ozempic out-of-pocket costs become unsustainable.

When compounded semaglutide saves money:

Scenario A: Your insurance doesn't cover Ozempic. If your plan denies coverage (common for weight-loss indications), your choice is cash-pay Ozempic ($940 to $1,150) or compounded semaglutide ($179 to $279). Compounded saves $660 to $870 monthly.

Scenario B: Your copay exceeds $200 and you don't qualify for the savings card. Medicare patients, Medicaid patients in non-coverage states, and TRICARE patients often face $200+ out-of-pocket. Compounded semaglutide at $179 to $279 becomes cheaper than the insured copay.

Scenario C: You're in the deductible phase and need to start immediately. A patient with a $4,000 deductible starting Ozempic in January faces $3,000+ out-of-pocket before insurance cost-sharing begins. Compounded semaglutide at $179 per month for three months ($537 total) is substantially cheaper than three fills of brand-name Ozempic at $1,050 each ($3,150 total).

When brand-name Ozempic is the better choice:

Scenario D: Your copay with savings card is under $100. If your post-deductible copay is $75 and the savings card reduces it to $25, brand-name Ozempic is cheaper than compounded semaglutide. The convenience of a pre-filled pen and FDA approval add value at this price point.

Scenario E: You qualify for the patient assistance program. Free brand-name Ozempic through the PAP is better than $179 compounded semaglutide. Always check PAP eligibility before switching to compounded.

Scenario F: You strongly prefer FDA-approved medications. Compounded semaglutide is not FDA-approved. It's prepared by a state-licensed compounding pharmacy under section 503A or 503B of the Federal Food, Drug, and Cosmetic Act. Patients who prioritize FDA approval should stay with brand-name Ozempic if cost allows.

How to calculate your exact out-of-pocket in 10 minutes

Step 1: Log into your insurance member portal. Navigate to the prescription drug section. Search for "semaglutide" or "Ozempic" in the formulary lookup tool. Note the tier placement (Tier 2, Tier 3, Tier 4, or specialty).

Step 2: Check your deductible status. In the same portal, find your deductible progress. Note how much you've spent toward your deductible this year and how much remains. If your deductible is $3,000 and you've spent $500, you have $2,500 remaining.

Step 3: Calculate deductible-phase cost. Divide your remaining deductible by the negotiated rate for Ozempic (typically $850 to $1,050 per fill). If you have $2,500 remaining and Ozempic costs $1,000 per fill, you'll pay full price for 2.5 fills (approximately three months).

Step 4: Identify your post-deductible copay. Your formulary lookup should show the copay or coinsurance for Ozempic's tier. Tier 3 typically shows a dollar amount ($75, $150, $200). Tier 4 typically shows a percentage (25%, 30%, 40%). If it's a percentage, multiply by the negotiated rate. 30% of $1,000 = $300 copay.

Step 5: Apply the savings card (if eligible). If you have commercial insurance and your prescription is for type 2 diabetes, download the Novo Nordisk savings card. Subtract $150 from your post-deductible copay, with a floor of $25. If your copay is $200, your cost with the card is $50. If your copay is $75, your cost with the card is $25.

Step 6: Verify at the pharmacy. Call your pharmacy (or use the pharmacy's app) and ask them to run a test claim for Ozempic against your insurance. They'll return your exact copay without filling the prescription. Bring your savings card information and ask them to apply it to the test claim.

This six-step process takes 10 minutes and produces your specific out-of-pocket number, not an estimate.

When your out-of-pocket will change mid-year

Your Ozempic out-of-pocket cost is not static. Four events trigger mid-year cost changes.

Event 1: Meeting your deductible. The most common cost change. Your out-of-pocket drops from full negotiated rate ($850 to $1,050) to your plan's copay ($25 to $300) the month after you meet your deductible. For patients with $3,000+ deductibles, this typically happens in March or April.

Event 2: Reaching your out-of-pocket maximum. If your total healthcare spending hits your plan's out-of-pocket maximum ($5,000 to $9,100 for individual coverage), your Ozempic cost drops to $0 for the remainder of the calendar year. This is uncommon for patients using only Ozempic but frequent for patients who have surgery or other high-cost care.

Event 3: Prior authorization denial or expiration. Most insurance plans require prior authorization (PA) for Ozempic, typically approved for 6 to 12 months. If your PA expires and isn't renewed, the pharmacy will reject the claim and you'll pay cash price until PA is resubmitted and approved. PA renewals require provider action, not patient action, but patients experience the cost impact.

Event 4: Formulary changes. Insurance companies update formularies quarterly or annually. Ozempic can move from Tier 3 to Tier 4 (or vice versa) mid-year, changing your copay. Formulary changes are communicated via mail or email 30 to 60 days in advance, but many patients don't notice until they fill the prescription.

The January reset. Every January 1, your deductible and out-of-pocket maximum reset to $0. Patients who paid $25 per month in December will pay $1,000+ in January (deductible phase). This reset is the most common source of patient complaints about "unexpected" cost increases.

The prior authorization trap and its cost impact

Prior authorization (PA) is an insurance requirement that your provider submit clinical documentation proving Ozempic is medically necessary before the plan will cover it.

What triggers PA requirements:

• First-time Ozempic prescription (initial PA)
• Dose increase above 1 mg (step-edit PA)
• Switching from another GLP-1 medication (change-of-therapy PA)
• Annual renewal (continuation PA)

What providers must submit:

• Diagnosis code (E11.9 for type 2 diabetes)
• Recent A1C lab result (typically required to be above 7.0%)
• Documentation of prior medication trials (many plans require metformin failure first)
• BMI documentation
• Treatment plan and expected outcomes

PA approval timeline:

• Urgent PA: 24 to 72 hours
• Standard PA: 3 to 14 business days
• Appeal after denial: 15 to 30 days

The cost impact of PA delays: If you start Ozempic before PA approval, you pay cash price ($940 to $1,150). If PA is approved retroactively, some plans reimburse the difference between cash price and copay. Many plans do not.

A 2025 study of 12,000 Ozempic prescriptions found that 42% required PA, 18% of PAs were denied on first submission, and the average time from prescription to PA approval was 9.3 days (Anderson et al., Journal of Managed Care Pharmacy 2025). Patients who filled prescriptions during the PA review period paid an average of $1,087 out of pocket, with only 31% receiving retroactive reimbursement after approval.

How to avoid the PA trap: Ask your provider to submit PA before writing the prescription. Most electronic health record systems allow PA submission without an active prescription. Waiting for PA approval before filling adds 7 to 10 days but prevents the $1,000+ cash-pay surprise.

FormBlends clinical pattern: the deductible-phase switch

Across our compounded semaglutide patient population, we observe a consistent enrollment pattern tied to calendar timing and deductible resets.

January through March accounts for 41% of new patient starts on compounded semaglutide, compared to 18% in October through December. The pattern holds across all insurance types, including patients with commercial insurance who would otherwise qualify for the Novo Nordisk savings card.

The driver is deductible-phase cost avoidance. Patients starting GLP-1 therapy in January face $3,000 to $4,000 in out-of-pocket spending on brand-name Ozempic before their deductible resets and copay assistance activates. Compounded semaglutide at $179 to $279 monthly allows patients to start therapy immediately at a predictable cost, then evaluate switching to brand-name Ozempic in April or May once the deductible is met and the savings card applies.

Approximately 22% of our Q1 compounded semaglutide patients transition to brand-name Ozempic in Q2 after meeting their deductible. The remaining 78% continue with compounded semaglutide, citing cost predictability, lack of insurance paperwork, and satisfaction with clinical outcomes.

This pattern suggests that even patients with good insurance coverage use compounded semaglutide as a deductible-phase bridge, not necessarily as a permanent alternative. The decision to switch or stay is driven by the post-deductible copay amount and savings card eligibility.

FAQ

How much is Ozempic out of pocket with insurance? With commercial insurance and the Novo Nordisk savings card, expect $25 to $75 per month after meeting your deductible. During the deductible phase (typically January through March), you pay the full negotiated rate of $850 to $1,050 per fill. Without the savings card, post-deductible copays range from $75 to $500 depending on formulary tier.

How much is Ozempic out of pocket without insurance? Uninsured cash price is $940 to $1,150 per month depending on pharmacy and location. Costco offers the lowest cash price at $895 to $980. GoodRx coupons reduce the price by 8% to 15%, bringing it to $820 to $960 at most pharmacies.

Does the Ozempic savings card work for Medicare patients? No. Federal law prohibits manufacturer copay assistance for Medicare, Medicaid, TRICARE, and other government insurance programs. Medicare patients pay their plan's specialty tier copay, typically $200 to $470 per month, with no copay card available.

What is the Ozempic patient assistance program? The NovoCare Patient Assistance Program provides free Ozempic to patients with income below 400% of federal poverty level ($60,240 for individuals) who lack prescription coverage or whose insurance denies Ozempic. The program ships medication directly to patients for up to 12 months, renewable annually.

Why is my Ozempic copay so high? High copays usually result from one of four causes: you haven't met your annual deductible yet, Ozempic is on a high formulary tier (Tier 4 or specialty), your prescription is for weight loss rather than type 2 diabetes (leading to denial), or your plan requires prior authorization that hasn't been approved.

How much is Ozempic out of pocket at Walmart? Walmart's cash price is $980 to $1,100 per month. With insurance, your cost depends on your plan's formulary tier and deductible status, typically $25 to $500. Walmart accepts the Novo Nordisk savings card, which can reduce eligible copays to $25 per fill.

Is compounded semaglutide cheaper than Ozempic? For patients without insurance or with high copays, yes. Compounded semaglutide costs $179 to $279 monthly compared to $940+ for cash-pay Ozempic. For patients with commercial insurance, savings card access, and copays under $100, brand-name Ozempic may be comparable or cheaper.

Can I use GoodRx if I have insurance? Yes, but not simultaneously. You can choose to use a GoodRx coupon instead of your insurance if the GoodRx price is lower than your copay. However, GoodRx payments don't count toward your deductible or out-of-pocket maximum, so this strategy delays reaching those thresholds.

How much is Ozempic out of pocket during the donut hole? Medicare Part D patients in the coverage gap (donut hole) pay 25% of the cost, typically $210 to $290 per fill. The donut hole begins after total drug spending reaches $5,030 and ends when out-of-pocket spending reaches $8,000, at which point catastrophic coverage begins.

Does Medicaid cover Ozempic? Coverage varies by state. Most state Medicaid programs cover Ozempic for type 2 diabetes with prior authorization and copays of $0 to $8. Coverage for weight loss is rare. Patients should check their state's Medicaid formulary or ask their provider to submit a PA.

What happens to my Ozempic cost when I meet my deductible? Your cost drops from the full negotiated rate ($850 to $1,050) to your plan's copay or coinsurance (typically $75 to $300). If you're eligible for the Novo Nordisk savings card, your cost drops further to as low as $25 per fill.

How long does the Ozempic savings card last? The card covers up to 24 fills or 24 months, whichever comes first. For patients filling monthly, the card expires after two years. Novo Nordisk does not currently offer a renewal or extension program. After expiration, you pay your plan's full copay.

Can I get a 90-day supply of Ozempic to reduce costs? Some insurance plans allow 90-day fills, which typically cost 2.5x to 2.85x the monthly copay rather than 3x, saving $30 to $75 per quarter. Not all plans cover 90-day fills for specialty medications. Check with your pharmacy or insurance to confirm eligibility.

What's the cheapest way to get Ozempic? For low-income patients, the NovoCare Patient Assistance Program provides free medication. For insured patients, the Novo Nordisk savings card reduces copays to $25. For uninsured patients, Costco offers the lowest cash price at $895 to $980. For patients with high copays or no coverage, compounded semaglutide at $179 to $279 is typically cheapest.

Does Ozempic cost more for higher doses? Cash price increases slightly with dose (0.5 mg costs $940, 2 mg costs $1,150), but the difference is small. With insurance, copays are usually the same regardless of dose because they're based on formulary tier, not medication strength. Some plans apply step-edit requirements for doses above 1 mg.

Sources

1. Cubanski J et al. Medicare Part D cost-sharing for high-cost drugs. Kaiser Family Foundation. 2025.
2. IQVIA National Prescription Audit. Semaglutide prescription volume and payer mix. 2025.
3. Anderson M et al. Prior authorization approval rates and timelines for GLP-1 receptor agonists. Journal of Managed Care Pharmacy. 2025.
4. GoodRx Research. Uninsured prescription fill rates by medication class. 2025.
5. National Community Pharmacists Association. Manufacturer copay card utilization and eligibility analysis. 2024.
6. Novo Nordisk. NovoCare Patient Assistance Program enrollment data. 2024.
7. Centers for Medicare & Medicaid Services. Medicare Part D benefit parameters. 2026.
8. U.S. Department of Health and Human Services. Federal poverty level guidelines. 2026.
9. Pharmacy Benefit Management Institute. Formulary tier structure and copay benchmarks. 2025.
10. GoodRx. Prior authorization survey: denial rates and appeal outcomes. 2024.
11. American Diabetes Association. Standards of Medical Care in Diabetes: Pharmacologic approaches to glycemic treatment. Diabetes Care. 2026.
12. Food and Drug Administration. Ozempic (semaglutide) prescribing information. Revised 2024.
13. Congressional Budget Office. Prescription drug pricing and manufacturer assistance programs. 2025.
14. National Association of Boards of Pharmacy. Compounding pharmacy regulation and 503A/503B distinctions. 2025.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, and Rybelsus are registered trademarks of Novo Nordisk A/S. Walmart, CVS, Walgreens, Costco, Sam's Club, and GoodRx are trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.